JPWO2019200254A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019200254A5
JPWO2019200254A5 JP2020555451A JP2020555451A JPWO2019200254A5 JP WO2019200254 A5 JPWO2019200254 A5 JP WO2019200254A5 JP 2020555451 A JP2020555451 A JP 2020555451A JP 2020555451 A JP2020555451 A JP 2020555451A JP WO2019200254 A5 JPWO2019200254 A5 JP WO2019200254A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
ruxolitinib
compound
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521170A (ja
JP2021521170A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027217 external-priority patent/WO2019200254A1/en
Publication of JP2021521170A publication Critical patent/JP2021521170A/ja
Publication of JPWO2019200254A5 publication Critical patent/JPWO2019200254A5/ja
Publication of JP2021521170A5 publication Critical patent/JP2021521170A5/ja
Priority to JP2024009550A priority Critical patent/JP2024038485A/ja
Pending legal-status Critical Current

Links

JP2020555451A 2018-04-13 2019-04-12 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤 Pending JP2021521170A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024009550A JP2024038485A (ja) 2018-04-13 2024-01-25 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862657540P 2018-04-13 2018-04-13
US201862657563P 2018-04-13 2018-04-13
US62/657,540 2018-04-13
US62/657,563 2018-04-13
US201862743469P 2018-10-09 2018-10-09
US62/743,469 2018-10-09
US201862753025P 2018-10-30 2018-10-30
US201862753023P 2018-10-30 2018-10-30
US62/753,023 2018-10-30
US62/753,025 2018-10-30
PCT/US2019/027217 WO2019200254A1 (en) 2018-04-13 2019-04-12 Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024009550A Division JP2024038485A (ja) 2018-04-13 2024-01-25 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2021521170A JP2021521170A (ja) 2021-08-26
JPWO2019200254A5 true JPWO2019200254A5 (https=) 2022-04-20
JP2021521170A5 JP2021521170A5 (https=) 2022-04-20

Family

ID=68164545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555451A Pending JP2021521170A (ja) 2018-04-13 2019-04-12 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤
JP2024009550A Pending JP2024038485A (ja) 2018-04-13 2024-01-25 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024009550A Pending JP2024038485A (ja) 2018-04-13 2024-01-25 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤

Country Status (9)

Country Link
US (2) US20210113562A1 (https=)
EP (1) EP3773560A4 (https=)
JP (2) JP2021521170A (https=)
KR (2) KR20260036611A (https=)
CN (3) CN117838695A (https=)
AU (2) AU2019252793A1 (https=)
CA (1) CA3095580A1 (https=)
MX (2) MX2020010556A (https=)
WO (1) WO2019200254A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
EP4611753A1 (en) * 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
MXPA06003054A (es) 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
CN101321760A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
BRPI0718029A2 (pt) 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US8846704B2 (en) 2007-01-31 2014-09-30 YM Biosciences Austraila Pty Ltd Thiopyrimidine-based compounds and uses thereof
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
MX2009009117A (es) 2007-03-01 2009-09-03 Supergen Inc Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
EP2217235A4 (en) 2007-11-15 2011-01-12 Musc Found For Res Dev INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
NZ586662A (en) 2007-12-19 2012-08-31 Vertex Pharma PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
AR070531A1 (es) 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
MX2011001426A (es) 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為pim激酶抑制劑之三唑吡啶化合物
AU2009289317A1 (en) 2008-09-02 2010-03-11 Novartis Ag Heterocyclic PIM-kinase inhibitors
WO2010026121A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
MX2011002365A (es) 2008-09-02 2011-04-04 Novartis Ag Derivados de picolinamida como inhibidres de cinasa.
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
AU2010236389A1 (en) 2009-04-15 2011-11-24 Nationwide Children's Hospital, Inc. Curcumin analogs as dual JAK2/STAT3 inhibitors and methods of making and using the same
BRPI1011066A2 (pt) 2009-05-20 2017-03-21 Cylene Pharmaceuticals Inc "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
EP2515665B1 (en) 2009-12-22 2013-08-14 Unilever NV A process for preparing a tea product
PL2516425T3 (pl) 2009-12-23 2016-03-31 Jasco Pharmaceuticals Llc Inhibitory kinaz aminopirydynowych
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
JP2013530199A (ja) 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
EP2614065B1 (en) 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
PL2678329T3 (pl) 2011-02-25 2016-06-30 Array Biopharma Inc Związki triazolopirydyny jako inhibitory kinaz pim
WO2012120415A1 (en) 2011-03-04 2012-09-13 Novartis Ag Tetrasubstituted cyclohexyl compounds as kinase inhibitors
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
ES2595407T3 (es) * 2011-06-14 2016-12-29 Novartis Ag Combinación de panobinostat y ruxolitinib en el tratamiento de cáncer, tal como una neoplasia mieloproliferativa
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2734205B1 (en) * 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN102924445B (zh) 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
WO2013059738A2 (en) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9173883B2 (en) 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
BR112015002709B1 (pt) 2012-08-06 2022-09-20 Acea Biosciences Inc Compostos, composição farmacêutica, uso dos mesmos e uso de uma combinação de composto ou composição farmacêutica e um segundo agente profilático ou agente terapêutico
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN102880459A (zh) 2012-08-14 2013-01-16 张涛 基于VisualLisp编程语言下的编译实现方法及系统
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
CN104812756A (zh) 2012-09-26 2015-07-29 曼凯德公司 多激酶通路抑制剂
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
WO2014130693A1 (en) 2013-02-25 2014-08-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びcyp3a4阻害剤の組み合わせ
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
HK1215374A1 (zh) 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
KR102094011B1 (ko) 2013-06-13 2020-03-26 삼성전자주식회사 전자 장치에서 노이즈를 제거하기 위한 장치 및 방법
JP6458018B2 (ja) 2013-07-02 2019-01-23 ファーマサイクリックス エルエルシー キナーゼ阻害剤としてのプリノン化合物
JP2016527305A (ja) * 2013-08-08 2016-09-08 ノバルティス アーゲー Pimキナーゼ阻害剤の組合せ
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2014354821A1 (en) * 2013-11-27 2016-05-26 Novartis Ag Combination therapy comprising an inhibitor of JAK, CDK and PIM
EP3102238A1 (en) * 2014-01-20 2016-12-14 Gilead Sciences, Inc. Therapies for treating cancers
PH12020552277A1 (en) 2014-04-08 2023-07-17 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US20150306112A1 (en) 2014-04-25 2015-10-29 National Cheng Kung University Zhankuic acid A, a JAK2/3 tyrosine kinase inhibitor, and a potential therapeutic agent for hepatitis
WO2016161248A1 (en) 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
CN105919955A (zh) * 2016-06-13 2016-09-07 佛山市腾瑞医药科技有限公司 一种鲁索利替尼制剂及其应用
WO2020146440A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
NZ778055A (en) * 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
WO2021080955A1 (en) * 2019-10-21 2021-04-29 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use

Similar Documents

Publication Publication Date Title
JP2021155426A5 (https=)
CL2025001163A1 (es) Compuestos para tratar cáncer.
CN116249683A8 (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JP2018127467A5 (https=)
JP2021521170A5 (https=)
UY39890A (es) Compuestos con diana en mutante de p53
JP2021528488A5 (https=)
JP2016515628A5 (https=)
JP2023166406A5 (https=)
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
JP2021523220A5 (https=)
CN115605475A (zh) 一种免疫抑制剂、其制备方法和应用
Awasthi et al. OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath
JP2017533220A5 (https=)
IL278345B1 (en) Methods of treating cancer
JP2018172383A5 (ja) 魚介類のベコ病の経口投与用治療剤組成物及びそれを用いた魚介類のベコ病の治療方法
JP2019065009A5 (https=)
JPWO2019200254A5 (https=)
JPWO2020257665A5 (https=)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
CN116406288A8 (zh) 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合,用于治疗癌症或冯-希佩尔-林道病的方法
JP2018507880A5 (https=)
DE2241470A1 (de) Arzneimittel mit antivirus-wirksamkeit
Schwartz et al. The Management of Massive Tuberculous Pneumonia, A Therapeutic Review of Seventy-Five Cases
NO952559D0 (no) N-acyl-pyrrolidiner og medikamenter for behandling eller prevensjon av cholecystokinin- og gastrin-relaterte mangler